<?xml version="1.0" encoding="UTF-8"?>
<ref id="dyaa033-B14">
 <label>14</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Arabi</surname>
    <given-names>YM</given-names>
   </name>, 
   <name name-style="western">
    <surname>Alothman</surname>
    <given-names>A</given-names>
   </name>, 
   <name name-style="western">
    <surname>Balkhy</surname>
    <given-names>HH</given-names>
   </name>
  </person-group>
  <etal>et al</etal>; and the MIRACLE Trial Group. 
  <article-title>Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial</article-title>. 
  <source>Trials</source>
  <year>2018</year>;
  <volume>19</volume>:
  <fpage>81</fpage>.
  <pub-id pub-id-type="pmid">29382391</pub-id>
 </mixed-citation>
</ref>
